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Predicting, or forecasting, outcomes is difficult and is central to the role of physicians in 
making clinical management decisions. The integration of knowledge, skills and experience 
to predict who will respond to a treatment, survive an operation or extract useful benefit 
from Intensive Care is something many readers of this journal will do daily. This becomes 
more difficult when both the event and the treatment are rare. In the linked article in this 
issue of Resuscitation1, Pasquier and colleagues test a tool, the Hypothermia Outcome 
Prediction after Extracorporeal Life Support (HOPE) score, for predicting outcomes in 
patients presenting with hypothermic cardiac arrest and treated by extra-corporeal life 
support (ECLS). True hypothermic cardiac arrest is relatively rare and hypothermic cardiac 
arrest with access to ECLS is even less frequent. The authors have made substantial progress 
widening our collective experience and formulating this into an easy to apply tool. 
Moreover, the way in which the tool has been generated provides some interesting lessons 
about predicting outcomes from rare events generally and more specifically in the context 
of hypothermic cardiac arrest.  
 
The authors derived the HOPE Score from a previous cohort of patients2. This cohort 
comprised 237 patients from published studies and 49 patients in the care records of two 
Swiss hospitals. The HOPE score probability of survival was derived from a multiple logistic 
regression of a larger number of variables and combines information for: age, sex, 
mechanism of cooling, core temperature, serum K+ level and duration of CPR. The accuracy 
of prediction of the score when applied to patients not in the cohort has been uncertain 
because, until now, the score had not been externally validated. In this paper, the authors 
attempt to provide this validation.  
 
The validation cohort comprised 122 patients, assembled by updating their search of 
published studies (after excluding patients included in the derivation study) and from the 
care records of three additional centres. The threshold for offering or not-offering ECLS 
(≥0.10 probability of survival) represents a decision point that balances the two opposing 
consequences of misclassifications – providing futile ECLS to a patient with no chance of 
recovery or failing to provide ECLS to a patient with the potential to recover. These 
consequences carry different weights and the threshold was chosen to minimise the specific 
risk of providing futile ECLS and not to minimise all misclassifications. The need for a 
threshold arises from the consequences of futile treatment: poor long term neurological 
outcome, emotional cost to the family, as well as the direct and indirect economic costs of 
ECLS.  
 
It is rare to be able to predict outcomes perfectly by applying one threshold. It is therefore 
unsurprising that there can be instances when the prediction appears wrong. These arise 
where the underlying distributions of scores associated with the two outcomes overlap or 
when applying the prediction rule outside the precise context in which it was developed and 
validated. Thus caution should be exercised when using the HOPE score in a deterministic 
fashion around this threshold value of 0.10. The instance of the young patient discussed by 
the authors might also make us cautious about using the HOPE score to predict outcome in 
children. 
 
The need for derivation and validation samples arises because a rule developed on a 
particular sample will be based in part on true underlying associations between predictors 
and the outcome of interest and in part on spurious associations (due to chance) between 
other predictors and the outcome. This leads to the performance of the rule being 
overestimated in the derivation sample. A validation sample is used to estimate the 
performance of the rule in an independent dataset. However, identifying an independent 
dataset can be challenging for two reasons, both of which arise from failing to specify the 
context in which the validated rule will be applied. Firstly, external factors that differ 
between the derivation and validation samples can influence the performance of the rule 
and secondly, if the validation sample is not sufficiently independent, then the performance 
will still be overestimated. Judging whether a validation sample eliminates spurious 
association is very difficult. This challenge can be illustrated by considering a dataset that is 
large enough to divide into two subsets – one for derivation and one for validation. 
Randomly allocating records to one or other subset might appear ideal. However, this 
randomises spurious as well as true associations – especially if the data were collected in a 
consistent way. The same might be true if the dataset were to be divided by date of cohort 
entry (or other non-random method); splitting a dataset by date also introduces the 
possibility that the performance of the rule might vary over time. To understand how 
applicable the HOPE score may be, it is important to ask whether the validation dataset 
should ideally have included records that would not have been included in the derivation 
dataset – for example, from centres that are less expert in treating hypothermic patients 
with ECLS. 
 
There is a difference between the patients reported in published datasets or treated in high-
volume centres and hypothermic patients at other centres where treatment decisions about 
ECLS may also be made. Successful implementation and outcome of ECLS in the emergency 
department relies on a well-rehearsed pathway, which is unusual for rare events. (There 
were 6,000 episodes of all extracorporeal cardiopulmonary resuscitation (ECPR) worldwide 
in 2018 (not just hypothermia) spread across 9,000 centres3; published 10-year experiences 
at two specialist centres yielded 114 and 485 patients respectively.) Since many of these 
cases will be concentrated in centres with a specialist interest, expecting the HOPE score to 
achieve a similar level of prediction in small volume centres is probably unrealistic. 
 
The HOPE validation dataset is relatively small. This limitation leads to imprecise estimates 
of its performance - confidence intervals for predictive values of living or dying given a 
particular HOPE score are not reported. Many risk prediction tools (eg EuroSCORE6, P-
POSSUM7) do not publish the CIs with their predicted risk – they should do. The CI, as well 
as the point estimate, describes the risk of misclassifications and is important when 
interpreting and applying a rule. Confidence intervals can change with the predicted risk 
(the EuroSCORE has narrow CIs in low risk patients and the CIs increase as the risk 
increases). Clinicians must have CIs presented alongside the calculated risk to be fully 
informed and adjust their decision making. 
 
Centres should reflect on how they currently make decisions about implementing ECLS. It is 
clear that using a serum potassium level alone to guide the decision to use ECLS in 
hypothermic cardiac arrest is inadequate and leads to futile care in a number of cases. We 
recommend that the HOPE score be widely adopted to inform decisions about using ECLS. 
Centres should systematically record the information required to calculate the score, hold 
these data securely and make them available for subsequent analysis. However, applying 
the HOPE score threshold systematically means that this data can only inform whether the 
threshold for treatment can be raised (i.e. avoiding some additional instances of futile care) 
since ECLS will not be offered to patients with a score below the threshold. By stratifying 
centres according to their experience or volume, analysis of these data should inform 
whether the survival threshold should be set at a higher level for low volume centres to 
avoid futile care. These data will not address the issue of the validity of using the HOPE 
score threshold in children, where the concern is that a lower threshold may be appropriate. 
Nonetheless, collecting the data required for the HOPE score would still be worthwhile for 
all children for whom a decision is made about treatment with ECLS. 
 
Both the number of centres using and the number of patients receiving ECLS are rising3 and 
we must begin to risk stratify its use on the basis of evidence rather than positively biased 
case reports leading to enthusiasm-based use. Whilst the HOPE score is not a perfect 
prediction tool, it is better than the way in which decisions are currently made and can only 
be improved by being updated with more recent, independent ‘test’ data. 
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